91 related articles for article (PubMed ID: 23885470)
1. [Molecular pathology - aspects in KRAS mutation analysis in colon carcinoma].
Hershkovitz D; Ben-lzhak O
Harefuah; 2013 Jun; 152(6):356-60, 367. PubMed ID: 23885470
[TBL] [Abstract][Full Text] [Related]
2. Accurate KRAS mutation testing for EGFR-targeted therapy in colorectal cancer: emphasis on the key role and responsibility of pathologists.
Hoorens A; Jouret-Mourin A; Sempoux C; Demetter P; De Hertogh G; Teugels E
Acta Gastroenterol Belg; 2010; 73(4):497-503. PubMed ID: 21299161
[TBL] [Abstract][Full Text] [Related]
3. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
[TBL] [Abstract][Full Text] [Related]
4. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples.
De Miglio MR; Mura A; Uras MG; Manca A; Contini M; Murgia L; Zinellu A; Sotgia S; Carru C; Massarelli G; Cossu-Rocca P
Diagn Mol Pathol; 2010 Dec; 19(4):201-8. PubMed ID: 21052001
[TBL] [Abstract][Full Text] [Related]
5. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
6. KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma.
Siyar Ekinci A; Demirci U; Cakmak Oksuzoglu B; Ozturk A; Esbah O; Ozatli T; Celik B; Budakoglu B; Turker I; Bal O; Turan N
J BUON; 2015; 20(1):128-35. PubMed ID: 25778307
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach.
Domagała P; Hybiak J; Sulżyc-Bielicka V; Cybulski C; Ryś J; Domagała W
Pol J Pathol; 2012 Nov; 63(3):145-64. PubMed ID: 23161231
[TBL] [Abstract][Full Text] [Related]
8. KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine.
Wang HL; Lopategui J; Amin MB; Patterson SD
Adv Anat Pathol; 2010 Jan; 17(1):23-32. PubMed ID: 20032635
[TBL] [Abstract][Full Text] [Related]
9. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation testing in colorectal cancer.
Plesec TP; Hunt JL
Adv Anat Pathol; 2009 Jul; 16(4):196-203. PubMed ID: 19546608
[TBL] [Abstract][Full Text] [Related]
11. Challenges posed to pathologists in the detection of KRAS mutations in colorectal cancers.
Dudley J; Tseng LH; Rooper L; Harris M; Haley L; Chen G; Gocke CD; Eshleman JR; Lin MT
Arch Pathol Lab Med; 2015 Feb; 139(2):211-8. PubMed ID: 25611103
[TBL] [Abstract][Full Text] [Related]
12. [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy].
Rako I; Jakić-Razumović J; Caban D; Sertić J; Katalinić D; Golem H; Plestina S
Lijec Vjesn; 2011; 133(11-12):403-7. PubMed ID: 22329297
[TBL] [Abstract][Full Text] [Related]
13. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
14. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
15. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
Carotenuto P; Roma C; Cozzolino S; Fenizia F; Rachiglio AM; Tatangelo F; Iannaccone A; Baron L; Botti G; Normanno N
Int J Oncol; 2012 Feb; 40(2):378-84. PubMed ID: 21971641
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutation analysis in a complex molecular diagnostic referral practice: the need for test redundancy.
Pang B; Ong CW; Chong ML; Muliana-Ismail T; Soong R; Salto-Tellez M
Pathology; 2012 Dec; 44(7):655-7. PubMed ID: 23172084
[No Abstract] [Full Text] [Related]
18. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
[TBL] [Abstract][Full Text] [Related]
19. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes and dendritic cells in human colorectal cancer: their relationship to KRAS mutational status and disease recurrence.
Kocián P; Šedivcová M; Drgáč J; Cerná K; Hoch J; Kodet R; Bartůňková J; Špíšek R; Fialová A
Hum Immunol; 2011 Nov; 72(11):1022-8. PubMed ID: 21884745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]